Peter Attia’s longevity model meets tougher scrutiny
- Attia says he has revised past claims about keto and prolonged fasting as evidence and trade-offs became clearer.
- Behind the Bastards questions whether costly screening and off-label drugs expose healthy patients to more risk than proven benefit.
Peter Attia’s longevity pitch is meeting two tests: whether its evidence holds up, and whether more prevention can actually help patients. In an episode covered Oct 12, 2026, The Peter Attia Drive featured Attia revisiting his own views. Behind the Bastards followed on Oct 13 and returned to the subject Oct 15, with Dr. Kaveh Hoda challenging the medical risks of some high-end longevity care. These are coverage dates, not dates for the medical practices or research discussed.
Attia said he once believed keto worked mainly by suppressing insulin, but now sees calorie reduction - often made easier by feeling full - as the key. He also reconsidered multi-day fasting: the hoped-for boost in autophagy, a cell’s recycling process, is hard to measure in people, while fasting can cost lean muscle and slow recovery. His position, as presented on The Peter Attia Drive, is that health advice should change when evidence does.
Hoda’s criticism on Behind the Bastards is that some longevity care moves from updating beliefs to offering interventions ahead of strong human evidence. He questioned routine scans, glucose monitors for people without diabetes, and colonoscopies at 40 for average-risk patients, compared with the recommended starting age of 45 he cited. He also said no Phase 3 human trials establish rapamycin’s safety for healthy adults using it for longevity; its immune-suppressing effects may bring serious risks.
The difference matters: Attia’s account describes revising theories, while Hoda argues that patients may still be exposed to tests and treatments whose benefits are unclear. Hoda cited a 2012 UC Davis study in which the most satisfied patients had a 26% higher risk of death than the least satisfied, connecting greater care and testing with possible harm - not proving that satisfaction itself caused it. He also estimated Attia’s clinic fees at $100,000 to $500,000 a year.
Together, the episodes leave a practical question rather than a verdict on prevention: does a test change what a doctor should do, and does a treatment have evidence in people like the patient receiving it? Attia’s willingness to revise some claims offers one answer about scientific humility. Hoda’s warning is that humility must also mean knowing when not to intervene.
Source Intelligence
- Deep dive into what was said in the episodes
Part Two: Peter Attia and the Cult of Longevity • Oct 15
- After McKinsey, Attia returned to public-facing medicine through talks, media, and the Nutrition Science Initiative; Kaveh says the role let Attia build a scientific profile without board certification, before opening his longevity clinic Early Medicine.
- Attia's clinic offered intensive testing and monitoring, including glucose monitors for non-diabetic patients, repeated lipid panels, VO2 max tests, MRI and DEXA scans, wearables, off-label drugs, and after-hours consultations; Kaveh estimates annual fees of $100,000 to $500,000.
- Kaveh argues that elite concierge clinics create a more unequal medical system: the care is inaccessible to most patients, may reset wealthy clients' expectations of ordinary doctors, and is unlikely to scale to the general population.
- Attia built a large audience through The Drive, celebrity appearances, and his book Outlive; Kaveh says the book's popularity helped make Attia a major wellness figure.
- Attia's Medicine 3.0 pitch emphasizes prevention, personalization, and data; Kaveh says Attia uses the claim that 90% of Americans have a metabolic-syndrome marker, although the clinical definition requires at least three markers and one abnormal result alone is less meaningful.
- Kaveh lists the five metabolic-syndrome markers as abdominal obesity, high triglycerides, low HDL, high blood pressure, and elevated fasting glucose; the condition raises risk of diabetes, coronary disease, and stroke, but he favors lifestyle changes before reflexive medication.
- Kaveh questions Attia's routine advanced cardiac testing, including APOB, LP(a), CRP, calcium scoring, and coronary CT, because some tests have not been shown to improve outcomes and can trigger radiation exposure and further procedures; he says each test should change management to justify its use.
- Kaveh supports colorectal screening but says average-risk patients should start at 45, while Attia pushes for 40; younger-onset cases are increasing, but Kaveh says absolute risk remains low and earlier testing should depend on risk factors or symptoms.
- Kaveh cites a 2012 UC Davis study in which the most satisfied patients spent more on healthcare, had more hospital admissions, and faced higher mortality; a 2019 Cochrane review also found risks from overdiagnosis and unnecessary treatment.
- Kaveh says continuous glucose monitors have no established benefit for people without diabetes and can cause anxiety, restrictive eating, and unnecessary expense; Attia advertised for Dexcom, and the company said his advisory role ended in 2021.
- Kaveh says Attia overextends limited evidence on zone-two exercise, cancer, and diet: glucose use by cancer cells does not establish that avoiding sugar slows cancer, and evidence does not support ketogenic diets, prolonged fasting, or calorie restriction as longevity treatments.
- Attia prescribes rapamycin off-label for longevity despite the absence of phase-three trials; Kaveh says animal evidence remains preliminary, human evidence is limited, and immunosuppression can raise infection, lymphoma, and metabolic risks.
- Kaveh says Attia's authority comes partly from speaking fluently about data while operating beyond his formal training in cardiovascular disease, endocrinology, neurodegeneration, and nutrition; Kaveh sees this as science-washing that can lend credibility to MAHA and anti-vaccine figures.
- Kaveh says Attia's critique of Medicine 2.0 understates gains from vaccines, antibiotics, and conventional research; Attia's own praise of immunotherapy relies on advances produced by that system, while diseases such as cancer and Alzheimer's affect more people because public health has extended lifespans.
- Kaveh frames Attia as a warning about doctors serving wealthy, famous patients: the desire to please powerful people can push clinicians beyond appropriate care, while influence and a polished public persona can outrun evidence and medical guardrails.
Also discussed on this episode: (8)
Health (3)
- Kaveh says Peter Attia spent two years at McKinsey after leaving residency, working on corporate risk rather than medical projects; Attia later described the job as a period of systems-level thinking.
- McKinsey advised Purdue Pharma on growing OxyContin sales, including targeting high-volume prescribers and promoting higher-dose pills; Kaveh says the firm also helped counter public-health warnings and knowingly misled the FDA through overlapping assignments.
- Kaveh says Attia's book recounts that he stayed in New York while his one-month-old son was hospitalized after nearly dying, despite his wife's requests that he return; Epstein emails show Attia arranging to meet him during that same ICU period.
Enterprise (1)
- Kaveh says McKinsey accepted responsibility for a misdemeanor charge tied to misbranding prescription drugs, while senior partner Martin Elling faced felony obstruction charges; the firm also cut its global workforce and drew criticism over Enron and work with authoritarian governments.
Society (2)
- Attia met Jeffrey Epstein in 2014, years after Epstein's 2008 conviction, and exchanged medical advice, referrals, and business help with him; Kaveh says Attia met Epstein about 10 times, stayed in a New York apartment, and expressed interest in visiting the island and Zorro Ranch, with no evidence he went to the ranch.
- Epstein introduced Attia to a foreign-born model who was later identified as one of Epstein's victims; Attia sought Epstein's help hiring her for his clinic, while emails cited by Kaveh indicate visa issues prevented the hire.
Longevity (1)
- Emails show Attia discussing sex and longevity with Epstein, including a 2016 offer to add years to Epstein's life for more sex; Attia also wrote that he could not tell anyone about Epstein's life, while later saying he never witnessed illegal behavior or saw anyone who appeared underage.
Media (1)
- After Epstein-file revelations, Attia left a CBS contributor role and parted ways with David and AG1; Kaveh says wearable company Oura also distanced itself from Attia, who is now suing the company.
Part One: Peter Attia and the Cult of Longevity • Oct 13
- Dr. Kaveh Hoda describes longevity medicine as a proactive model aimed at extending healthspan through geroscience. However, its top tier relies on experimental drugs that currently lack robust trial evidence in humans.
- Dr. Kaveh Hoda notes that concierge medicine accelerates healthcare collapse by shrinking physician patient loads from thousands down to a few hundred. This dynamic restricts access almost exclusively to wealthy clients.
- Dr. Kaveh Hoda argues that ignoring small-scale wellness quackery and unproven medical claims gradually degrades public scientific literacy. This passive acceptance ultimately undermines trust in critical public health measures like vaccination.
Also discussed on this episode: (5)
Health (4)
- Dr. Kaveh Hoda cites medical research showing that patient outcomes during inpatient hospitalizations are better or equal when treated by female physicians compared to male physicians.
- Peter Attia was born in Toronto in 1973 to Egyptian parents. Before attending Stanford Medical School, Attia studied mechanical engineering and applied mathematics at Queen's University while competing in high-intensity endurance sports.
- During his general surgery residency at Johns Hopkins, Peter Attia created an unapproved Excel model to alter dosing schedules for the high-risk antibiotic gentamicin. Attia administered the drug without attending or pharmacy approval.
- Peter Attia abandoned his surgical residency in his fifth year, telling podcast host Jocko Willink that he resented the lack of meritocracy and standardized resident pay. Attia subsequently joined McKinsey & Company as a consultant.
Labor (1)
- Dr. Kaveh Hoda explains that medical residencies previously exceeded 80 hours per week before labor regulations instituted an 80-hour work limit, though older practitioners often considered the restriction overly lenient.
#411 ‒ AMA #90: Strong convictions, loosely held: how Peter's views on fasting, keto, metformin, rapamycin, whole-body MRI, and exercise have changed • Oct 12
- Attia adopted the phrase strong convictions loosely held from a hedge fund manager to describe updating health theses when contradictory data emerges. Attia notes scientists must prioritize reducing uncertainty over defending original claims.
- Attia states that publishing identical medical guidance a decade after writing his book would indicate either rigid personal thinking or a complete lack of scientific progress.
- Attia updates his clinical views through a combination of evolving scientific literature, deep-dive discussions with expert podcast guests, and direct clinical observations from patient outcomes.
- Attia adhered to a strict ketogenic diet for 3 years, averaging morning fasting beta-hydroxybutyrate levels between 1.8 and 2.0 millimoles. Attia eventually abandoned the diet due to lifestyle restrictions rather than health concerns.
- Attia previously attributed ketogenic diet efficacy to insulin suppression under the carbohydrate-insulin model. Attia now believes ketogenic diets work primarily by helping patients naturally manage total energy intake through satiety.
- Attia asserts that metabolic dysfunction, visceral fat accumulation, and impaired insulin sensitivity stem from energy imbalances rather than hyperinsulinemia. Patients on ketogenic diets can still gain weight if maintaining an energy surplus.
- Attia remains agnostic on specific dietary structures as long as foundational metabolic targets are met. Attia requires patients to consume at least 1.4 grams of protein per kilogram of body weight daily.
- Attia previously conducted quarterly fasts of 7 to 10 days alongside monthly 3-day fasts to induce cellular autophagy. Attia undertook these protocols for longevity benefits rather than weight loss.
- Autophagy functions as an analog cellular recycling process where nutrient deprivation forces cells to degrade damaged organelles and pre-senescent structures. Attia highlights preclinical data showing significant autophagy acceleration requires roughly 3 days of fasting.